一个关于BET抑制剂的小概述:超越代体向的目标
Mikhail S Iudin1,2, Yuri M Khodarovich3,4, Anna M Varizhuk1,2
1Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
Biomedicines
|March 28, 2025
概括
非基因抑制剂通过向基因和额外终端域 (BET) 蛋白来提供一种新的治疗策略,这些蛋白质对于基因转录至关重要,并与癌症和病毒感染等疾病有关.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 基因和额外终端域 (BET) 蛋白质是参与基因转录的关键表观遗传读者.
- BET蛋白的失调与癌症,代谢障碍和病毒感染有关,使它们成为治疗点.
- 目前的研究主要集中在odomain抑制上,但这种方法有局限性.
研究的目的:
- 审查最近在开发非原体BET抑制剂方面取得的进展.
- 讨论这些新型抑制剂的潜在应用,优势和未来前景.
主要方法:
- 最近科学出版物的文献综述.
- 对非原体BET抑制剂的新兴研究进行分析.
- 对治疗潜力和挑战的研究结果的综合.
主要成果:
- 非基因BET抑制剂为基因抑制剂提供了一个有前途的替代品.
- 这些抑制剂可以更好地控制宿主和病毒基因表达.
- 准非乳腺原蛋白区域可能会减轻与广谱抑制相关的副作用.
结论:
- 非原体BET抑制剂在针对BET蛋白进行治疗干预方面取得了重大进展.
- 需要进一步的研究和开发,才能充分发挥其在治疗各种疾病方面的潜力.
- 这些抑制剂提供了一种更精确的方法来调节依赖BET的转录调节.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Targets for Drug Action: Overview
9.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.4K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Inhibitors of Viral Protein Synthesis
73
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73


